This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor compared to placebo in patients with type 2 diabetes. The anticipated time on study treatment is < 3 months and the target sample size is 100-500 individuals.

Inclusion Criteria:

• adult patients 18-75 years of age;
• type 2 diabetes diagnosed >=1 month before screening;
• no previous treatment, or previous treatment with no more than 2 oral medications.

Exclusion Criteria:

• type 1 diabetes;
• type 2 diabetes treated with insulin or a PPAR gamma agonist during the 3 months before screening;
• patients who are pregnant, breastfeeding or not using a reliable contraceptive method.